Global Neutropenia Treatment Market Size, Status and Forecast 2019-2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered
- 1.4 Market Analysis by Type
- 1.4.1 Global Neutropenia Treatment Market Size Growth Rate by Type (2014-2025)
- 1.4.2 Granulocyte -colony- stimulating factor (G-CSF)
- 1.4.3 Antibiotics
- 1.4.4 Antifungal drugs
- 1.5 Market by Application
- 1.5.1 Global Neutropenia Treatment Market Share by Application (2014-2025)
- 1.5.2 Hospital Pharmacy
- 1.5.3 Retail Pharmacy
- 1.5.4 Online Pharmacy
- 1.6 Study Objectives
- 1.7 Years Considered
2 Global Growth Trends
- 2.1 Neutropenia Treatment Market Size
- 2.2 Neutropenia Treatment Growth Trends by Regions
- 2.2.1 Neutropenia Treatment Market Size by Regions (2014-2025)
- 2.2.2 Neutropenia Treatment Market Share by Regions (2014-2019)
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
- 2.3.3 Market Opportunities
3 Market Share by Key Players
- 3.1 Neutropenia Treatment Market Size by Manufacturers
- 3.1.1 Global Neutropenia Treatment Revenue by Manufacturers (2014-2019)
- 3.1.2 Global Neutropenia Treatment Revenue Market Share by Manufacturers (2014-2019)
- 3.1.3 Global Neutropenia Treatment Market Concentration Ratio (CR5 and HHI)
- 3.2 Neutropenia Treatment Key Players Head office and Area Served
- 3.3 Key Players Neutropenia Treatment Product/Solution/Service
- 3.4 Date of Enter into Neutropenia Treatment Market
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
- 4.1 Global Neutropenia Treatment Market Size by Type (2014-2019)
- 4.2 Global Neutropenia Treatment Market Size by Application (2014-2019)
5 United States
- 5.1 United States Neutropenia Treatment Market Size (2014-2019)
- 5.2 Neutropenia Treatment Key Players in United States
- 5.3 United States Neutropenia Treatment Market Size by Type
- 5.4 United States Neutropenia Treatment Market Size by Application
6 Europe
- 6.1 Europe Neutropenia Treatment Market Size (2014-2019)
- 6.2 Neutropenia Treatment Key Players in Europe
- 6.3 Europe Neutropenia Treatment Market Size by Type
- 6.4 Europe Neutropenia Treatment Market Size by Application
7 China
- 7.1 China Neutropenia Treatment Market Size (2014-2019)
- 7.2 Neutropenia Treatment Key Players in China
- 7.3 China Neutropenia Treatment Market Size by Type
- 7.4 China Neutropenia Treatment Market Size by Application
8 Japan
- 8.1 Japan Neutropenia Treatment Market Size (2014-2019)
- 8.2 Neutropenia Treatment Key Players in Japan
- 8.3 Japan Neutropenia Treatment Market Size by Type
- 8.4 Japan Neutropenia Treatment Market Size by Application
9 Southeast Asia
- 9.1 Southeast Asia Neutropenia Treatment Market Size (2014-2019)
- 9.2 Neutropenia Treatment Key Players in Southeast Asia
- 9.3 Southeast Asia Neutropenia Treatment Market Size by Type
- 9.4 Southeast Asia Neutropenia Treatment Market Size by Application
10 India
- 10.1 India Neutropenia Treatment Market Size (2014-2019)
- 10.2 Neutropenia Treatment Key Players in India
- 10.3 India Neutropenia Treatment Market Size by Type
- 10.4 India Neutropenia Treatment Market Size by Application
11 Central & South America
- 11.1 Central & South America Neutropenia Treatment Market Size (2014-2019)
- 11.2 Neutropenia Treatment Key Players in Central & South America
- 11.3 Central & South America Neutropenia Treatment Market Size by Type
- 11.4 Central & South America Neutropenia Treatment Market Size by Application
12 International Players Profiles
- 12.1 Amgen
- 12.1.1 Amgen Company Details
- 12.1.2 Company Description and Business Overview
- 12.1.3 Neutropenia Treatment Introduction
- 12.1.4 Amgen Revenue in Neutropenia Treatment Business (2014-2019)
- 12.1.5 Amgen Recent Development
- 12.2 Novartis
- 12.2.1 Novartis Company Details
- 12.2.2 Company Description and Business Overview
- 12.2.3 Neutropenia Treatment Introduction
- 12.2.4 Novartis Revenue in Neutropenia Treatment Business (2014-2019)
- 12.2.5 Novartis Recent Development
- 12.3 Teva Pharmaceutical
- 12.3.1 Teva Pharmaceutical Company Details
- 12.3.2 Company Description and Business Overview
- 12.3.3 Neutropenia Treatment Introduction
- 12.3.4 Teva Pharmaceutical Revenue in Neutropenia Treatment Business (2014-2019)
- 12.3.5 Teva Pharmaceutical Recent Development
- 12.4 Hospira
- 12.4.1 Hospira Company Details
- 12.4.2 Company Description and Business Overview
- 12.4.3 Neutropenia Treatment Introduction
- 12.4.4 Hospira Revenue in Neutropenia Treatment Business (2014-2019)
- 12.4.5 Hospira Recent Development
- 12.5 Pfizer
- 12.5.1 Pfizer Company Details
- 12.5.2 Company Description and Business Overview
- 12.5.3 Neutropenia Treatment Introduction
- 12.5.4 Pfizer Revenue in Neutropenia Treatment Business (2014-2019)
- 12.5.5 Pfizer Recent Development
13 Market Forecast 2019-2025
- 13.1 Market Size Forecast by Regions
- 13.2 United States
- 13.3 Europe
- 13.4 China
- 13.5 Japan
- 13.6 Southeast Asia
- 13.7 India
- 13.8 Central & South America
- 13.9 Market Size Forecast by Product (2019-2025)
- 13.10 Market Size Forecast by Application (2019-2025)
14 Analyst's Viewpoints/Conclusions
15 Appendix
- 15.1 Research Methodology
- 15.1.1 Methodology/Research Approach
- 15.1.1.1 Research Programs/Design
- 15.1.1.2 Market Size Estimation
- 12.1.1.3 Market Breakdown and Data Triangulation
- 15.1.2 Data Source
- 15.1.2.1 Secondary Sources
- 15.1.2.2 Primary Sources
- 15.1.1 Methodology/Research Approach
- 15.2 Disclaimer
Neutropenia is an abnormal condition, characterized by critically low levels of circulating neutrophils, a type of WBC found in the blood. These cells make up for the majority of circulating lymphocytes and help defend the body against infections by bacteria, viruses, and other pathogenic organisms. Decrease in the neutrophil count in blood makes a patient susceptible to infections and may even prove fatal. Therefore, the condition requires immediate prophylaxis.
Novel therapies combined with growing cases of chemotherapy-induced neutropenia is one of the primary drivers for market growth. Moreover, the novel drug delivery technique also improves patient convenience leading to better patient adherence thus driving the market growth. Furthermore, since cancer is the known cause for developing neutropenia, the increasing cases of chemotherapy for the treatment of cancer will be a growth driver for the neutropenia treatment market.
In 2018, the global Neutropenia Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Neutropenia Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Neutropenia Treatment development in United States, Europe and China.
The key players covered in this study
Amgen
Novartis
Teva Pharmaceutical
Hospira
Pfizer
...
Market segment by Type, the product can be split into
Granulocyte -colony- stimulating factor (G-CSF)
Antibiotics
Antifungal drugs
Market segment by Application, split into
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Neutropenia Treatment status, future forecast, growth opportunity, key market and key players.
To present the Neutropenia Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Neutropenia Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.